|
| Study | Subjects | Serum Tests | Results |
|
| Alessandri et al., 2004 [124] | Prospective cohort study of 43 patients with RA not responding to DMARDs treated with infliximab in combination with methotrexate | Serum samples collected and tested for anti-CCP antibodies and RF at baseline and after 24 weeks | (i) Serum titres of anti-CCP and RF decreased significantly after 24 weeks of treatment (anti-CCP −14%; RF −20%)
(ii) Significant decreases in serum anti-CCP antibodies and RF observed only in patients with clinical improvement |
|
| Atzeni et al., 2006[128] | 57 patients with RA not responsive to methotrexate treated with adalimumab as part of the ReAct open-label phase IIIb study | Serum samples collected and tested for anti-CCP antibodies and RF at baseline and after 24 and 48 weeks of followup | (i) Treatment resulted in significant decreases in anti-CCP serum levels at 24 weeks (−14%) and 48 weeks (−33%)
(ii) Treatment resulted in significant decreases in RF serum levels at 24 weeks (−33%) and 48 weeks (−42%)
(iii) The decrease in anti-CCP and RF antibody titers correlated with the clinical response to the therapy |
|
| Bobbio-Pallavicini et al., 2004 [131] | Prospective study of 30 consecutive patients with RA; patients were followed during 78 weeks of infliximab and methotrexate therapy for refractory rheumatoid arthritis | Serum samples collected and tested for anti-CCP antibodies and RF at baseline and after 30, 54 and 78 weeks | (i) % patients positive for RF, Anti-CCP approximately same at baseline and 78 weeks
(ii) Median RF titre underwent progressive reduction from 128 IU/mL to 53 IU/mL
(iii) Anti-CCP antibody titre significantly decreased at 30 weeks but returned to baselinev |
|
| Caramaschi et al., 2005 [133] | Prospective cohort study of 27 patients with refractory RA treated with infliximab and methotrexate | Serum samples collected and tested for anti-CCP antibodies, Rf and CRP at baseline and after 22 weeks | (i) Serum levels of anti-CCP antibodies did not change from baseline with infliximab treatment
(ii) IgM RF and CRP levels decreased significantly with infliximab treatment |
|
| Chen et al., 2006 [130] | 90 patients with RA who failed treatment with DMARDs; randomized clinical protocol in which all 90 patients continued DMARD treatment and 52 patients were assigned for additional treatment with etanercept | Serum samples collected and tested for anti-CCP and RFat baseline and one month intervals for three months during the treatment course | (i) Serum anti-CCP levels decreased 31.3% in patients positive for anti-CCP at baseline treated with etanercept
(ii) Serum RF levels decreased 36% in patients positive for RF at baseline treated with etanercept
(iii) Decreases in serum anti-CCP and RF levels were progressive throughout the three-month treatment course
(iv) Changes in anti-CCP levels was positively correlated with changes in various clinical measures of RA |
|
| De Rycke et al., 2005 [132] | Prospective cohort study of 62 patients with refractory RA treated with infliximab combined with methotrexate | Serum samples collected and tested for anti-CCP antibodies, IgM RF, CRP and ESR at baseline and after 30 weeks | (i) RF titres significantly reduced at baseline and week 30 during infliximab treatment
(ii) Anti-CCP antibodies unchanged by infliximab treatment
(iii) IgM RF titres correlated inversely with changes in CRP and ESR; Anti-CCP antibodies did not correlate inversely with these biomarkers |
|
| Mikuls et al., 2004 [126] | Retrospective study of serum samples from 66 RA patients who completed double-blind, randomized clinical protocols (1) methotrexate, hydroxychloroquine, and sulfasalazine, (2) minocycline versus placebo, and (3) minocycline versus hydroxychloroquine | Serum samples collected at baseline and at a followup averaging 13.7 months ± 8.6 months; Samples were stored at −80° and later and tested for anti-CCP antibodies and RF | (i) 52% of patients positive for anti-CCP antibodies at baseline had >25% reduction in anti-CCP antibody levels during treatment course
(ii) 55% of patients positive for RF at baseline had >25% reduction in RF levels during treatment course
(iii) Significant reductions in anti-CCP levels was only seen in patients with disease duration <12 months
(iv) No association was seen between reductions in anti-CCP levels and treatment response
(v) Significant reductions in RF levels were determined by treatment response |
|
